Pancreatic polypeptide family motifs, polypeptides and methods comprising the same

• US 8,906,849 B2
• Filed: 04/08/2013
• Issued: 12/09/2014
• Est. Priority Date: 02/11/2004
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC), Amylin Pharmaceuticals LLC (Bristol-Myers Squibb Company)
• Inventors: Levy, Odile Esther, Jodka, Carolyn M., Ghosh, Soumitra S., Parkes, David G., Pittner, Richard A., D'Souza, Lawrence J., Ahn, John S., Prickett, Kathryn S., Roth, Jonathan David, Adams, Sean H.
• Primary Examiner(s): HEARD, THOMAS SWEENEY
• Application Number:
  US13/858,398
• Publication Number:
  US 20130303442A1
• Time in Patent Office: 610 Days
• US Class Current: 514/4.8
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.

Claims

1. A method for treating Type-2 diabetes, obesity, or insulin-resistance syndrome, or for causing weight loss, in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a PPF polypeptide to treat obesity, Type-2 diabetes, or insulin-resistance syndrome, or to cause weight loss, wherein the PPF polypeptide comprises the amino acid sequence of Formula (VII) (SEQ ID NO:

482);

2. The method of claim 1 for treating Type 2 diabetes.

3. The method of claim 1 for treating obesity in the mammal in need thereof.

4. The method of claim 1, wherein the PPF polypeptide comprises the amino acid sequence set forth in SEQ ID NO:

438.

5. The method of claim 1, wherein the PPF polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

266, 437, 438, 439, 442, 462, 469, 470, 471, and 472.

6. The method of claim 1, wherein the PPF polypeptide further comprises an N-terminal cap.

7. The method of claim 1, wherein the PPF polypeptide is linked to one or more water-soluble polymers.

8. The method of claim 7, wherein the polymer is selected from at least one of the group consisting of polyethylene glycol and a fatty acid molecule, wherein the polymer is linked to the N- or C-terminus of the polypeptide, or the side chain of a lysine or serine amino acid residue within the sequence of the polypeptide.